Meta-analysis of 13 immunohistochemical studies assessing Bcl-2 with the same antibody clone as used in this study revealed that Bcl-2 was associated with better survival for NSCLC patients (HR = 0.71, 95% CI 0.61-0.83) however this study was biased in favor of positive trials [22]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.